Impact of generic substitution on levetiracetam serum concentration —A prospective study in an outpatient setting

In the European Union, LEV was approved under the brand name Keppra ® in September 2000. Since the expiration of the patent, several generic LEV preparations have been marketed. Switching patients from a branded AED preparation to a generic one with the same active ingredient is often a challenging task. Several studies have shown that considerable proportions of p atients report either a deterioration in seizure control or increased adverse effects, enforcing a switch back to the original preparation (Andermann et al., 2007; Chaluvadi et al., 2011; Fitzgerald and Jacobson, 2011).

Source: Epilepsy Research - June 6, 2017 Category: Neurology Authors: Arne Reimers, Patrik Olsson, Johanna Nilsson, Elin Hoff, Margareta Reis, Maria Strandberg, Anders Lundgren, Kristina K ällén Source Type: research